Eli Lilly and AbCellera dosed the first patients in a Phase I study of a potential antibody treatment for COVID-19.
Bristol-Myers Squibb is taking aim at harnessing CRISPR-based solutions to treat certain cancers with a $65 million collaboration with Montreal-based Repare Therapeutics.
Merck exploded into the COVID-19 battle with three significant deals and collaborations.
Regeneron Pharmaceuticals will repurchase about $5 billion of the U.S. drugmaker’s shares directly from France’s Sanofi, without altering their 17-year partnership.
A high dose of filgotinib, the JAK1 inhibitor under long-term development by Gilead Sciences Inc. and Galapagos NV, proved effective in a Phase IIb/III study as a treatment for patients with moderately to severely active ulcerative colitis.
Weeks after Mammoth Biosciences announced the company’s CRISPR-based diagnostics test for COVID-19 had a high degree of specificity even for asymptomatic patients, the Bay Area-based firm struck a deal with GlaxoSmithKline to accelerate development of the test in hopes of getting them in consumer hands as soon as possible.
Shares of bluebird bio were down in trading after the U.S. Food and Drug Administration declined to review a Biologics License Application for the experimental CAR-T treatment idecabtagene vicleucel for multiple myeloma co-developed with Bristol Myers Squibb.
Thermo Fisher Scientific Inc. expanded the company’s response to the COVID-19 pandemic by developing a total antibodies test in collaboration with WuXi Diagnostics and Mayo Clinic.
Waltham, Massachusetts-based biotech firm Skyhawk Therapeutics is expanding a strategic collaboration deal with Merck as the two companies are working to develop and commercialize a particular type of therapy built on modulating RNA splicing using Skyhawk’s SkySTAR technology platform.
Cambridge, Massachusetts-based Dyno Therapeutics came out of stealth mode with an official launch of the company’s proprietary CapsidMap platform.
